Inhibition of complement C1s by sutimlimab (SUT) in patients with cold agglutinin disease (CAD): results on efficacy and safety from the randomized, placebo-controlled phase 3 CADENZA study (NCT03347422)
ONCOLOGY RESEARCH AND TREATMENT(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要